ArticleCytotherapy2019
Aggregation of human mesenchymal stem cells enhances survival and efficacy in stroke treatment.
Article in Cytotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 40 citations in OpenAlex.
- Potential of intranasal delivery of human mesenchymal stem cells and extracellular vesicles for stroke therapy.Acta biomaterialia · 2026Review
- Human Stem Cell-Derived Extracellular Vesicles: A Pioneering Path from Biogenesis to Cerebral Ischemic Stroke Therapy.International journal of molecular sciences · 2025Review
- Clinical trials and advanced MRI techniques with stem cell therapy for ischemic stroke: present and future perspectives.Journal of translational medicine · 2025Review
- Cargo Analysis and MRI-Based Therapeutic Assessment of Iron Oxide Labelled Extracellular Vesicles of Hypoxia Human Stem Cells in Ischemic Stroke.Journal of extracellular biology · 2025Article
- Bibliometric Analysis and Visualized Study of Research on Mesenchymal Stem Cells in Ischemic Stroke.Stem cell reviews and reports · 2025Review
- Characteristics of Parthenogenetic Stem Cells and Their Potential Treatment Strategy for Central Nervous System Diseases.Neuropsychiatric disease and treatment · 2025Review
- Engineering human bone marrow-derived mesenchymal stromal cell aggregates for enhanced extracellular vesicle secretion in a vertical-wheel bioreactor.Frontiers in bioengineering and biotechnology · 2025Article
- Superparamagnetic Iron Oxide Nanoparticle-Labeled Extracellular Vesicles for Magnetic Resonance Imaging of Ischemic Stroke.ACS applied nano materials · 2024Article
- Priming and Combined Strategies for the Application of Mesenchymal Stem Cells in Ischemic Stroke: A Promising Approach.Molecular neurobiology · 2024Review
- EMF treatment delays mesenchymal stem cells senescence during long-termFrontiers in cell and developmental biology · 2024Article
- Engineering Extracellular Matrix-Bound Nanovesicles Secreted by Three-Dimensional Human Mesenchymal Stem Cells.Advanced healthcare materials · 2023Article
- Multinuclear MRI Reveals Early Efficacy of Stem Cell Therapy in Stroke.Translational stroke research · 2023Article
- Engineering Human Mesenchymal Bodies in a Novel 3D-Printed Microchannel Bioreactor for Extracellular Vesicle Biogenesis.Bioengineering (Basel, Switzerland) · 2022Article
- Extended Ischemic Recovery After Implantation of Human Mesenchymal Stem Cell Aggregates Indicated by Sodium MRI at 21.1 T.Translational stroke research · 2022Article
- Engineering extracellular vesicles by three-dimensional dynamic culture of human mesenchymal stem cells.Journal of extracellular vesicles · 2022Article
- Current Status of Mesenchymal Stem/Stromal Cells for Treatment of Neurological Diseases.Frontiers in molecular neuroscience · 2022Review
- Extracellular Vesicle Collection from Human Stem Cells Grown in Suspension Bioreactors.Methods in molecular biology (Clifton, N.J.) · 2022Article
- From Vial to Vein: Crucial Gaps in Mesenchymal Stromal Cell Clinical Trial Reporting.Frontiers in cell and developmental biology · 2022Review
- NODDI highlights recovery mechanisms in white and gray matter in ischemic stroke following human stem cell treatment.Magnetic resonance in medicine · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Human mesenchymal stem cells (hMSCs) have been shown to enhance stroke lesion recovery by mediating inflammation and tissue repair through secretion of trophic factors. However, low cell survival and reduced primitive stem cell function of culture-expanded hMSCs are the major challenges limiting hMSC therapeutic efficacy in stroke treatment. In this study, we report the effects of short-term preconditioning of hMSCs via three-dimensional (3D) aggregation on stroke lesion recovery after intra-arterial (IA) transplantation of 3D aggregate-derived hMSCs (Agg-D hMSCs) in a transient middle cerebral artery occlusion (MCAO) stroke model. Compared with two-dimensional (2D) monolayer culture, Agg-D hMSCs exhibited increased resistance to ischemic stress, secretory function and therapeutic outcome. Short-term preconditioning via 3D aggregation reconfigured hMSC energy metabolism and altered redox cycle, which activated the PI3K/AKT pathway and enhanced resistance to in vitro oxidative stress. Analysis of transplanted hMSCs in MCAO rats using ultra-high-field magnetic resonance imaging at 21.1 T showed increased hMSC persistence and stroke lesion reduction by sodium (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.